Passage BIO, Inc.PASG
What Passage BIO, Inc. does.
We are a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. We believe we have developed a differentiated approach to developing treatments for central nervous system, or CNS, disorders that allows us to select and advance product candidates with a higher probability of technical and regulatory success.
Our lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 is a gene replacement therapy that utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, or GRN , encoding progranulin, or PGRN, to the brain via intra cisterna magna, or ICM, administration. The lead indication for PBFT02 is frontotemporal dementia, or FTD, caused by progranulin deficiency, or FTD- GRN . We believe this clinical product candidate has the potential to provide patients with significantly improved outcomes given the rigorous capsid and transgene selection process, and our chosen route of ICM administration, which provides the potential for enhanced benefits due to widespread vector delivery to the brain and spinal cord and an improved safety profile compared with systemic administration, due to the lower doses required .
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$112.2M | -$185.4M | -$136.1M | -$102.1M | -$64.8M | -$45.5M |
| Free cash flow | — | — | — | — | -$48.0M | — |
More on PASG.
- Passage BIO, Inc. summary
- Passage BIO, Inc. financial statements
- Passage BIO, Inc. key metrics
- Passage BIO, Inc. health scores and style box
- Passage BIO, Inc. earnings
- Passage BIO, Inc. dividends
- Passage BIO, Inc. valuation
- Passage BIO, Inc. ownership and insiders
- Passage BIO, Inc. peers
Figures from Passage BIO, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.